These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11253915)

  • 1. Orally active GPIIb/IIIa antagonists: synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4.
    Kitamura S; Fukushi I; Miyawaki T; Kawamura M; Terashita E; Naka T
    Chem Pharm Bull (Tokyo); 2001 Mar; 49(3):268-77. PubMed ID: 11253915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel non-peptide GPIIb/IIIa antagonists: synthesis and biological activities of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic acids.
    Kitamura S; Fukushi H; Miyawaki T; Kawamura M; Terashita Z; Sugihara H; Naka T
    Chem Pharm Bull (Tokyo); 2001 Mar; 49(3):258-67. PubMed ID: 11253914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.
    Weller T; Alig L; Beresini M; Blackburn B; Bunting S; Hadváry P; Müller MH; Knopp D; Levet-Trafit B; Lipari MT; Modi NB; Müller M; Refino CJ; Schmitt M; Schönholzer P; Weiss S; Steiner B
    J Med Chem; 1996 Aug; 39(16):3139-47. PubMed ID: 8759635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
    Sugihara H; Fukushi H; Miyawaki T; Imai Y; Terashita Z; Kawamura M; Fujisawa Y; Kita S
    J Med Chem; 1998 Feb; 41(4):489-502. PubMed ID: 9484499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
    Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
    J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
    J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: synthesis and pharmacological evaluation of 2-oxopiperazine derivatives.
    Kitamura S; Fukushi H; Miyawaki T; Kawamura M; Konishi N; Terashita Z; Naka T
    J Med Chem; 2001 Jul; 44(15):2438-50. PubMed ID: 11448226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPIIb/IIIa integrin antagonists with the new conformational restriction unit, trisubstituted beta-amino acid derivatives, and a substituted benzamidine structure.
    Hayashi Y; Katada J; Harada T; Tachiki A; Iijima K; Takiguchi Y; Muramatsu M; Miyazaki H; Asari T; Okazaki T; Sato Y; Yasuda E; Yano M; Uno I; Ojima I
    J Med Chem; 1998 Jun; 41(13):2345-60. PubMed ID: 9632368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.
    Hutchinson JH; Cook JJ; Brashear KM; Breslin MJ; Glass JD; Gould RJ; Halczenko W; Holahan MA; Lynch RJ; Sitko GR; Stranieri MT; Hartman GD
    J Med Chem; 1996 Nov; 39(23):4583-91. PubMed ID: 8917647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ring constrained analogues of beta-alanine-containing GPIIb/IIIa receptor antagonists.
    Sielecki TM; Wityak J; Liu J; Mousa SA; Thoolen M; Wexler RR; Olson RE
    Bioorg Med Chem Lett; 2000 Mar; 10(5):449-52. PubMed ID: 10743945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig.
    André P; Arbeille B; Drouet V; Hainaud P; Bal dit Sollier C; Caen JP; Drouet LO
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):56-63. PubMed ID: 8548427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.
    Su T; Naughton MA; Smyth MS; Rose JW; Arfsten AE; McCowan JR; Jakubowski JA; Wyss VL; Ruterbories KJ; Sall DJ; Scarborough RM
    J Med Chem; 1997 Dec; 40(26):4308-18. PubMed ID: 9435900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists.
    Robarge KD; Dina MS; Somers TC; Lee A; Rawson TE; Olivero AG; Tischler MH; Webb RR; Weese KJ; Aliagas I; Blackburn BK
    Bioorg Med Chem; 1998 Dec; 6(12):2345-81. PubMed ID: 9925295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
    Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
    Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.
    Müller TH; Weisenberger H; Brickl R; Narjes H; Himmelsbach F; Krause J
    Circulation; 1997 Aug; 96(4):1130-8. PubMed ID: 9286940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of an orally active GPIIb/IIIa antagonist based on a phenylpiperazine scaffold.
    van Maarseveen JH; den Hartog JA; Tipker K; Reinders JH; Brakkee J; Schön U; Kehrbach W; Kruse CG
    Bioorg Med Chem Lett; 1998 Jun; 8(12):1531-6. PubMed ID: 9873384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists.
    Lawson EC; Hoekstra WJ; Addo MF; Andrade-Gordon P; Damiano BP; Kauffman JA; Mitchell JA; Maryanoff BE
    Bioorg Med Chem Lett; 2001 Oct; 11(19):2619-22. PubMed ID: 11551763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308.
    Hoekstra WJ; Maryanoff BE; Damiano BP; Andrade-Gordon P; Cohen JH; Costanzo MJ; Haertlein BJ; Hecker LR; Hulshizer BL; Kauffman JA; Keane P; McComsey DF; Mitchell JA; Scott L; Shah RD; Yabut SC
    J Med Chem; 1999 Dec; 42(25):5254-65. PubMed ID: 10602710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.